News coverage about Champions Oncology (NASDAQ:CSBR) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Champions Oncology earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.5706856856043 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Champions Oncology (CSBR) traded up $0.20 during midday trading on Tuesday, hitting $3.51. The stock had a trading volume of 45,900 shares, compared to its average volume of 53,105. Champions Oncology has a 1 year low of $1.71 and a 1 year high of $4.79.
Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings results on Thursday, September 14th. The biotechnology company reported ($0.06) EPS for the quarter. Champions Oncology had a negative net margin of 13.39% and a negative return on equity of 783.60%. The firm had revenue of $5.03 million for the quarter.
Champions Oncology Company Profile
Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.